Proton pump inhibitors decrease efficacy of palbociclib in patients with metastatic breast.
Javier Álvarez CriadoPilar Zamora AuñonVirginia Martínez MarínMacarena GarcíaTrevijano CabetasVictoria Lucía Collada SánchezEnrique Espinosa ArranzJosé Antonio Romero-GarridoJuana Benedi-GonzálezMariana Díaz AlmirónAlicia Herrero AmbrosioPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
This study demonstrates that the concurrent use of PPIs in mBC patients receiving palbociclib negatively affects PFS, particularly in the first-line setting. Nevertheless, further investigation is warranted to explore the impact of PPIs on cycle-dependent kinase 4/6 inhibitors.
Keyphrases